Palisade Bio Q4 EPS $(0.25) Beats $(0.34) Estimate
Portfolio Pulse from Happy Mohamed
Palisade Bio (NASDAQ:PALI) reported a Q4 EPS loss of $(0.25), surpassing the analyst consensus estimate of $(0.34) by 26.47%. This represents a significant improvement from the $(16.16) per share loss reported in the same quarter last year.
March 27, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Palisade Bio reported a smaller than expected Q4 EPS loss of $(0.25), outperforming the consensus estimate of $(0.34) and marking a significant year-over-year improvement.
The significant beat on EPS estimates and the dramatic improvement from last year's losses suggest a positive outlook for PALI, likely leading to increased investor confidence and potential short-term stock price appreciation.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100